The impact of FTAs on public health policies and TRIPS flexibilities
by Pedro Roffe, Christoph Spennemann
International Journal of Intellectual Property Management (IJIPM), Vol. 1, No. 1/2, 2006

Abstract: This paper, after providing a brief historical overview of the ways international agreements deal with public health-related IPRs, analyses the TRIPS-plus trend in Free Trade Agreements (FTAs) and its impact on access-to-medicines policies. It focuses on FTAs concluded by the USA and the Member states of the European Free Trade Association (EFTA) with a number of developing countries and their provisions on patents and test data protection. New obligations in this field go well beyond the TRIPS minimum standards and may seriously affect access in developing countries to affordable generic pharmaceutical products.

Online publication date: Tue, 03-Oct-2006

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com